Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Efficacy of Lumitrace (MB-102) and MediBeacon System
NCT05943977Phase 3Completed
- Sponsor
- Huadong Medicine
- Start
- Mar 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of relmapirazin in Kidney disease (4 arms), sponsored by Huadong Medicine. Primary endpoints: Area under the plasma concentration-time curve from time zero to infinity at 24 hours and Correlation of transdermal derived glomerular filtration rate to the plasma-derived indexed glomerular filtration rate at 24 hours. Started Mar 2023; status: completed.
02
Drugs
relmapirazin
03
Conditions
Kidney disease
Beyond the preview
Go deeper on NCT05943977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05943977.